AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03194789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy
Description: Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
Study NCT03194789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Pelvic Floor Therapy
Description: Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
Study NCT03267069 — intervention group
Intervention type: OTHER
Intervention: survey
Description: surveys will be administered at inclusion and follow-ups
Study NCT02116127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
Study NCT02116127 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
Study NCT01107522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO
Description: Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
Study NCT01107522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO and Temodar®
Description: Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle
Study NCT01107522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO, Temodar®, Radiation therapy
Description: Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
Study NCT03187730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Smoking Cessation and Financial Counseling
Description: Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
Study NCT03187730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Integrated Smoking Cessation and Financial Counseling
Description: Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
Study NCT03187730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Participants in both arms will be eligible to receive a free four-week supply of NRT.
Study NCT03187730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Participants in both arms will be eligible to receive a free four-week supply of NRT.
Study NCT01659983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary wound closure
Description: A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
Study NCT01659983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary wound closure
Description: A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
Study NCT03048747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
Study NCT02801617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-067
Description: 1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
Study NCT02801617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO-067
Description: 1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
Study NCT02801617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAAP Ofteno®
Description: 1 drop QD during 30 days Active comparator, reference medication.
Study NCT02801617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GAAP Ofteno®
Description: 1 drop QD during 30 days Active comparator, reference medication.
Study NCT00683618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Capsule/Tablet, oral, qd, 6 or 12 weeks
Study NCT00683618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Capsule/Tablet, 10mg, oral, qd, 6 weeks
Study NCT03950414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV specific T-cells
Description: Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~* Low Dose Tier - Viral-Specific T cell infusion 5 x10\^3 cells/kg body weight(BW)~* Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10\^4 cells/kg BW~* High Dose Tier - Viral-Specific T cell infusion 2.5 x10\^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection.
Study NCT02133560 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video recording
Description: Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
Study NCT02133560 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication Administration Log
Description: Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
Study NCT02133560 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation.
Study NCT03280524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Study NCT03280524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: self-care guidelines with feet
Study NCT03280524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-care guidelines with feet
Study NCT03385993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology based guided meditation and relaxation
Description: Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
Study NCT02439541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10\^7)
Study NCT02275819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
Study NCT00921609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
Study NCT00204919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: once-monthly vitamin D oral capsules (50,000 units)
Study NCT00204919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once-monthly placebo capsules
Study NCT00954941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 SE and HCTZ
Description: Treatment A - fixed dose combination
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 SE and HCTZ
Description: Treatment A - fixed dose combination
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 SE
Description: Treatment B - Monocomponent
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 SE
Description: Treatment B - Monocomponent
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: Treatment B -Monocomponent
Study NCT02176512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: Treatment B -Monocomponent
Study NCT00954941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
Study NCT00954941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
Study NCT01894841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide (CLASP)
Description: 6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
Study NCT01894841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety Assessment and Follow Up Evaluation
Description: enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
Study NCT01894841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Safety Assessment and Follow Up Evaluation
Description: enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
Study NCT02531022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
Study NCT00435695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK163090
Study NCT03307772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT03307772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics
Study NCT03307772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics and Probiotics
Study NCT03307772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01719367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Study NCT02019264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin hydrochloride
Description: APD356 10 mg twice daily
Study NCT02019264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT02344238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ID Capsule
Description: Capsule containing ingestible sensor
Study NCT02344238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Riboflavin
Description: 50mg
Study NCT02344238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prompts
Description: Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
Study NCT03289026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
Study NCT02295826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
Study NCT02295826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
Study NCT02183883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade > 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg.
Study NCT03397498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogniFit™
Description: The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
Study NCT03397498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-games
Description: The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
Study NCT03309943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
Study NCT03309943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one dose of Placebo on two separate occasions.
Study NCT02596204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Review
Description: Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
Study NCT02596204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: All subjects will wear a FitBit activity monitor.
Study NCT02596204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: All subjects will wear a FitBit activity monitor.
Study NCT03454308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMASH
Description: Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
Study NCT03454308 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced SC
Description: Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
Study NCT01664052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505 (Essure, BAY1454033)
Description: Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
Study NCT03825029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pillow
Description: A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
Study NCT03677284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time assistive products
Description: The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
Study NCT03677284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information brochure
Description: The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
Study NCT03677284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information brochure
Description: The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
Study NCT03721874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2.
Study NCT03721874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to Dapagliflozin 10 mg
Description: The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2.
Study NCT03999151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
Study NCT03999151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)